FDA Approves Lenvatinib (Lenvima) for Liver Cancer FDA Approves Lenvatinib (Lenvima) for Liver Cancer
The oral therapy lenvatinib joins sorafenib as the only drugs approved for first-line treatment of patients with unresectable hepatocellular carcinoma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Lenvima (lenvatinib) for First-line Treatment of Unresectable Hepatocellular Carcinoma (HCC)
Woodcliff Lake, NJ and Kenilworth, NJ, Aug. 16, 2018 – Eisai Inc. and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor Lenvima... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 16, 2018 Category: Drugs & Pharmacology Source Type: news

Two-year-old boy battling rare cancer risks blindness as painful mass grows over his eye
Muhammad Junaid, from a small village in Mirpur Khas, Pakistan, suffers from Retinoblastoma - a type of carcinoma that usually affects children under the age of five. (Source: the Mail online | Health)
Source: the Mail online | Health - August 16, 2018 Category: Consumer Health News Source Type: news

Blood test could detect kidney cancer up to five years prior to clinical diagnosis
(Beth Israel Deaconess Medical Center) A team of investigators led by Beth Israel Deaconess Medical Center (BIDMC) medical oncologist Rupal Bhatt, M.D., Ph.D., has demonstrated that a molecule called KIM-1, a protein present in the blood of some patients with renal cell carcinoma is present at elevated levels at the time of diagnosis, can also serve as a tool to predict the disease's onset up to five years prior to diagnosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 16, 2018 Category: Cancer & Oncology Source Type: news

A review of prevalent methods for automatic skin lesion diagnosis
(Bentham Science Publishers) The three prevalent skin cancers, according to the literature are melanoma, basal cell carcinoma and squamous cell carcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 15, 2018 Category: International Medicine & Public Health Source Type: news

Gut-microbiome Biomarkers Identify Early Hepatocellular Carcinoma Gut-microbiome Biomarkers Identify Early Hepatocellular Carcinoma
Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 10, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news

British Scientists Identify Kidney Cancer's Cellular Origin
Researchers from Wellcome Sanger Institute, the University of Cambridge and the University of Newcastle discovered that adult renal carcinoma cells are a version of a specific rare subtype of healthy adult kidney cell, called PT1. They found that despite genetic differences, all the renal carcinoma cells studied had developed the same PT1 characteristics. These results could provide the basis of a new method for treating cancer by targeting the PT1 cell specifically.08/10/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 10, 2018 Category: Urology & Nephrology Source Type: news

Lumpectomy Plus RT Tied to Lower Mortality in DCIS Lumpectomy Plus RT Tied to Lower Mortality in DCIS
Lumpectomy plus radiation is associated with a small but statistically significant reduced risk for breast cancer-related death compared to the other major options for ductal carcinoma in situ (DCIS).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 10, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Association of radiation therapy plus lumpectomy in reduced risk of dying in women with DCIS
(JAMA Network) Lumpectomy plus radiation was associated with a small clinical benefit in reduced risk of breast cancer death compared with lumpectomy or mastectomy alone   in women   with ductal carcinoma in situ (DCIS), a noninvasive early form of breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 10, 2018 Category: Cancer & Oncology Source Type: news

Renal Cell Carcinoma and Myelodysplastic Syndrome Show Epigenetic Association
Hypermethylation has been documented in some myeloid disorders including myelodysplastic syndrome (MDS) and in renal cell carcinoma (RCC). A group at the Mayo Clinic noticed the epigenetic marking patterns between these vastly different conditions and wondered if there was a connection. The group found that there was a strong association.08/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 9, 2018 Category: Urology & Nephrology Source Type: news

Frequent Skin Cancers May Signal Risk of Others
For the study, the researchers analyzed the DNA of 61 patients with frequent basal cell carcinomas, and found 20 percent had mutations in genes that help repair DNA damage in body cells. Cancer arises when such abnormal cells grow and spread unchecked. (Source: WebMD Health)
Source: WebMD Health - August 9, 2018 Category: Consumer Health News Source Type: news

Multiple bouts of ‘harmless’ skin cancer may triple risks of other cancers, study finds
People who develop multiple basal cell carcinomas, like Hugh Jackman, are at up to three-fold greater risk of getting another cancer, new Stanford University research suggests. (Source: the Mail online | Health)
Source: the Mail online | Health - August 9, 2018 Category: Consumer Health News Source Type: news

The Prevention of HBV-Related Hepatocellular Carcinoma The Prevention of HBV-Related Hepatocellular Carcinoma
This article discusses risk stratification of HBV-related hepatocellular carcinoma and summarizes three levels of preventive strategies.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 9, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Common skin cancer can signal increased risk of other cancers, Stanford researchers say
(Stanford Medicine) People who develop abnormally frequent cases of a skin cancer known as basal cell carcinoma appear to be at significantly increased risk for the development of other cancers, including blood, breast, colon and prostate cancers, according to a preliminary study by researchers at the Stanford University School of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 9, 2018 Category: Cancer & Oncology Source Type: news

Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors
Messenger RNA encodes cellular function and phenotype. In the context of human cancer, it defines the identities of malignant cells and the diversity of tumor tissue. We studied 72,501 single-cell transcriptomes of human renal tumors and normal tissue from fetal, pediatric, and adult kidneys. We matched childhood Wilms tumor with specific fetal cell types, thus providing evidence for the hypothesis that Wilms tumor cells are aberrant fetal cells. In adult renal cell carcinoma, we identified a canonical cancer transcriptome that matched a little-known subtype of proximal convoluted tubular cell. Analyses of the tumor compos...
Source: ScienceNOW - August 9, 2018 Category: Science Authors: Young, M. D., Mitchell, T. J., Vieira Braga, F. A., Tran, M. G. B., Stewart, B. J., Ferdinand, J. R., Collord, G., Botting, R. A., Popescu, D.-M., Loudon, K. W., Vento-Tormo, R., Stephenson, E., Cagan, A., Farndon, S. J., Del Castillo Velasco-Herrera, M., Tags: Development, Medicine, Diseases reports Source Type: news

Biomarkers May Predict TKI Response In Metastatic RCC
Angiogenesis-related biomarkers regulated by hypoxia were found to be strong predictors of primary renal tumor response (PRT), progression-free survival (PFS), and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who were being treated with sunitinib prior to kidney removal, according to research published in Clinical Cancer Research.108/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

Sunitinib vs Nephrectomy Followed By Sunitinib In Metastatic Renal Cell Carcinoma
In an interim analysis of the French phase III noninferiority Carmena trial reported in The New England Journal of Medicine, M éjean et al found that sunitinib alone was not inferior in overall survival vs nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic clear cell renal cell carcinoma.08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

Results From The Carmena Trial
Arnaud M éjean, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses his study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for patients with metastatic renal cell carcinoma (Abstract LBA3).08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

VEGF TKI + Immunotherapy Combinations For mRCC
This video discusses strategies for metastatic renal cell carcinoma that involve I-O therapies in combination with VEGF-targeted therapies.08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

Dr. Drake On The Role of Cytoreductive Nephrectomy In RCC
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia ’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma (RCC).08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

New Evidence May Help Improve Management Of Rare Kidney Cancers
Researchers have identified relapse patterns of nonclear cell renal cell carcinomas — an understudied group of rare kidney cancers — that are distinct from the more common clear cell renal cell carcinomas. The findings may help improve the management of patients with nonclear cell renal cell carcinomas (non-ccRCC), who represent approximately 20 percent of kidney cancer patien t populations.08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

Young Mother Has Hope and Health After a New Technique for Treating Kidney Cancer
Twenty-two weeks into her third pregnancy, Jessica Dykstra experienced incredible joy and intense fear --- in just a few minutes. Jessica learned she was having a baby girl to complement her two toddler boys. And just minutes before, the 25-year-old San Diego resident was diagnosed with stage 2 renal cell carcinoma — a malignant tumor on her left kidney.08/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 7, 2018 Category: Urology & Nephrology Source Type: news

Pre-Op Vismodegib May Spare Eye, Reduce Disfigurement in Basal-Cell Carcinoma Pre-Op Vismodegib May Spare Eye, Reduce Disfigurement in Basal-Cell Carcinoma
Treating periocular basal-cell carcinoma with vismodegib before surgery may reduce the size of the tumor, make the surgery less disfiguring and help preserve the eye, according to a single-center study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 7, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Cytoreductive Nephrectomy May Still Remain Standard For Some With Metastatic Renal Cell Carcinoma
The addition of cytoreductive nephrectomy to treatment with sunitinib malate did not provide a survival benefit for intermediate and poor-risk patients with metastatic renal cell carcinoma, according to results of the phase 3 CARMENA clinical trial presented at ASCO Annual Meeting.08/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 6, 2018 Category: Urology & Nephrology Source Type: news

Medical News Today: New drug may improve liver cancer therapy
Hepatocellular carcinoma (liver cancer) is fast growing, has poor survival rates, and has inefficient current treatments. Can they be improved? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 6, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Update on Atypical Ductal Hyperplasia Update on Atypical Ductal Hyperplasia
Biomarkers indicating progression to carcinoma are needed for atypical ductal hyperplasia.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 6, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk
Treatment of hepatitis C (HCV) with direct-acting antiviral agents does not appear to increase the risk of hepatocellular carcinoma (HCC) in individuals with cirrhosis, researchers from France report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 3, 2018 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Scientists develop novel drug that could potentially treat liver cancer more effectively
(National University of Singapore) A research team led by scientists from the Cancer Institute of Singapore at the National University of Singapore has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma or primary liver cancer. This landmark discovery opens door for more effective treatment of liver cancer with less side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 2, 2018 Category: Cancer & Oncology Source Type: news

Pulse Biosciences ’ nano-pulse stimulation tested in skin cancer patients
Pulse Biosciences, Inc. (Nasdaq:PLSE) has begun a clinical study to evaluate nano-pulse stimulation (NPS) platform in a common skin cancer, basal cell carcinoma (BCC). NPS is a non-thermal therapy that uses ultra-short, nanosecond-pulsed electric fields that directly affect and disrupt intracellular structures. It has been shown to induce immunogenic cell death in pre-clinical cancer models, according to the company. Study participants will be treated with NPS prior to resection of the BCC lesion, which is the standard of care for such lesions. Post-resection tissue samples will be assessed for the elimination of the ...
Source: Mass Device - August 1, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Clinical Trials Food & Drug Administration (FDA) Legal News Oncology Pulse Biosciences Securities & Exchange Commission (SEC) Source Type: news

Certain Renal Cancer Subtypes Linked to Obesity
Obesity is associated with development of clear cell and possibly chromophobe renal cell carcinoma (RCC), but not papillary RCC, according to researchers.07/31/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 31, 2018 Category: Urology & Nephrology Source Type: news

Combined assessment of low PGRMC1/positive ATP1A1 levels has enhanced prognostic value for renal cell carcinoma
Progesterone receptor membrane component 1 (PGRMC1) and Na+/K+ ‑ATPase α1 subunit (ATP1A1) are two proteins associated with the clinical prognosis of renal cell carcinoma (RCC) and RCC cell proliferation. However, the two proteins have been previously studied independently, and their combined influence on the clinical outcome of RCC remains unclear.07/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 27, 2018 Category: Urology & Nephrology Source Type: news

Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies
Targeted therapies, in particular antiangiogenic therapies (AATs), have become the standard of treatment for metastatic renal cell carcinoma (mRCC). Although common adverse effects like fatigue have been well-established, sexual disorders induced by these treatments, although often reported, have been poorly evaluated.07/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 27, 2018 Category: Urology & Nephrology Source Type: news

Second Primary Malignancy Risk Doubled After Head and Neck Cancer Second Primary Malignancy Risk Doubled After Head and Neck Cancer
The risk of second primary malignant neoplasm (SPMN) doubles after a first head and neck squamous cell carcinoma (HNSCC), especially when the site of the first cancer is not typically associated with malignancies due to human papillomavirus (HPV), according to a retrospective study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 27, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis
Treatment of patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease (ESRD) on dialysis poses a therapeutic challenge, particularly as this patient group was excluded from the pivotal clinical trials. In addition, there is uncertainty regarding drug dosing/pharmacokinetics, lack of safety and efficacy data, and potential for increased toxicity when using targeted therapy or immunotherapy for the management of patients with mRCC on dialysis.07/25/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 25, 2018 Category: Urology & Nephrology Source Type: news

Comprehensive analysis of a novel lncRNA profile reveals potential prognostic biomarkers in clear cell renal cell carcinoma
Clear cell renal cell carcinoma (ccRCC) is the main subtype of malignant kidney cancer. Long non ‑coding RNA (lncRNA) serves a key role in predicting survival in patients with cancer.07/25/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 25, 2018 Category: Urology & Nephrology Source Type: news

HPV Vaccine Eliminates Advanced Skin Cancer in 97-Year-Old
TUESDAY, July 24, 2018 -- The 9-valent human papillomavirus (HPV) vaccine could be a therapeutic option for patients with cutaneous squamous cell carcinoma when surgical management is not an option, according to a case report published online July 3... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 24, 2018 Category: Pharmaceuticals Source Type: news

French Receives Research Grant from St. Baldrick ’s Foundation
Christopher French, MD, of the Department of Pathology, was awarded a research grant from the St. Baldrick ’s Foundation for his project focusing on the pediatric and young adult cancer, NUT midline carcinoma (NMC), a rare and aggressive form of squam (Source: BWH News)
Source: BWH News - July 24, 2018 Category: Hospital Management Source Type: news

Pazopanib/Cetuximab Combo Promising in Recurrent, Metastatic Head and Neck Squamous Cell Carcinoma
A Washington University School of Medicine team ’s findings might inform future research into inhibitors of angiogenesis and PD-1 in head and neck cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 23, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma
Studies show that ZHX2 could be used as a potential therapeutic target for ccRCC.07/20/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 23, 2018 Category: Urology & Nephrology Source Type: news

Mesothelioma Case Report Touts Success with Opdivo
Not every mesothelioma patient benefits from the immunotherapy drug Opdivo, but for the ones that do, the response can be lifesaving. Opdivo, known generically as nivolumab, continues to produce dramatic results, inching it closer to FDA approval for mesothelioma cancer. A recently published individual case report describes “an exceptional and sustained response.” Treatment with Opdivo allowed one patient to go from a downward spiral, with only weeks to live, back into the workforce. “We were blown away by the patient’s response,” lead author Riley Jones, now in his fellowship at the Universit...
Source: Asbestos and Mesothelioma News - July 23, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

America ’s Drinking Habits Are Killing More Young People, Study Suggests
Liver disease deaths are growing more common in the U.S. and disproportionately affecting younger Americans, according to a recent study. The paper, published in The BMJ just a day after a Centers for Disease Control and Prevention (CDC) report on rising liver cancer death rates, paints a troubling picture of how Americans’ drinking habits may be affecting their health. While the new study couldn’t prove causation, the researchers say drinking is likely to blame for the growing number of adults aged 24 to 35 who are dying from cirrhosis, or scarring of the liver. The researchers used deaths logged in the CDC&r...
Source: TIME: Health - July 21, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime onetime Research Source Type: news

Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma
In a study reported in JAMA Oncology, Carlo et al found a high prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma (RCC).07/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 19, 2018 Category: Urology & Nephrology Source Type: news

Acute Kidney Injury in Patients With Cancer
Acute kidney injury (AKI) is a common complication in cancer patients and occurs in up to 30% of patients during their disease course. Multiple myeloma, leukemia/lymphoma, renal cell carcinoma, and hematopoietic stem cell transplantation are commonly associated with the development of AKI.07/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 19, 2018 Category: Urology & Nephrology Source Type: news

FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: World Pharma News)
Source: World Pharma News - July 19, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Skin Cancer Merkel Cell Carcinoma
Skin Cancer: Merkel Cell Carcinoma (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 19, 2018 Category: General Medicine Source Type: news

Discovery of kidney cancer driver could lead to new treatment strategy
(UNC Lineberger Comprehensive Cancer Center) In a study published in the journal Science, researchers suggest that ZHX2 is a potential new therapeutic target for clear cell renal cell carcinoma, which is the most common type of kidney cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2018 Category: International Medicine & Public Health Source Type: news

VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma
Inactivation of the von Hippel-Lindau (VHL) E3 ubiquitin ligase protein is a hallmark of clear cell renal cell carcinoma (ccRCC). Identifying how pathways affected by VHL loss contribute to ccRCC remains challenging. We used a genome-wide in vitro expression strategy to identify proteins that bind VHL when hydroxylated. Zinc fingers and homeoboxes 2 (ZHX2) was found as a VHL target, and its hydroxylation allowed VHL to regulate its protein stability. Tumor cells from ccRCC patients with VHL loss-of-function mutations usually had increased abundance and nuclear localization of ZHX2. Functionally, depletion of ZHX2 inhibited...
Source: ScienceNOW - July 19, 2018 Category: Science Authors: Zhang, J., Wu, T., Simon, J., Takada, M., Saito, R., Fan, C., Liu, X.-D., Jonasch, E., Xie, L., Chen, X., Yao, X., Teh, B. T., Tan, P., Zheng, X., Li, M., Lawrence, C., Fan, J., Geng, J., Liu, X., Hu, L., Wang, J., Liao, C., Hong, K., Zurlo, G., Parker, J Tags: Cell Biology, Medicine, Diseases reports Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - July 18, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: Roche Media News)
Source: Roche Media News - July 18, 2018 Category: Pharmaceuticals Source Type: news

Better Metastatic Renal Cell Carcinoma Survival at Higher-Volume Facilities Better Metastatic Renal Cell Carcinoma Survival at Higher-Volume Facilities
Patients with metastatic renal cell carcinoma (mRCC) treated at higher-volume facilities survive longer than those treated at lower-volume facilities, according to a registry-based analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 16, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news